 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Yuhan Corporation has decided to provide its new EGFR-mutated non-small cell lung cancer drug "Lexraza (component name Lazertinib)," which costs 73 million won per patient per year, free of charge for the time being.
"Let's make the best products and help the nation and our compatriots." Yuhan Corporation is because it will continue the maintenance of its founder, Dr. Yoo Il-han. Yuhan Corporation held a press conference on R&D and social contribution to Yuhan Corporation at The Plaza Hotel in Jung-gu, Seoul on the afternoon of the 10th. On the same day, President Cho Wook-je said, "Yuhan Corp. decided to implement Recraza's first treatment 'EAP' to inherit the founding spirit of its founder, Dr. Yoo Il-han," adding, "We will immediately implement the important idea of returning to society to prevent lung cancer patients from fighting the disease alone from having to bear the financial burden of treatment." The EAP (Early Access Program), also referred to as the sympathetic use approval program, is a program that supplies the drug free of charge for sympathetic purposes until it can be prescribed at the medical site.
AlphaBIZ 김지선(stockmk2020@alphabiz.co.kr)
